403 related articles for article (PubMed ID: 10223783)
1. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
2. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
3. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
4. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
[TBL] [Abstract][Full Text] [Related]
5. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
[TBL] [Abstract][Full Text] [Related]
8. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
Chodjania Y; Tharaux PL; Ragueneau I; Dussaule JC; Picker JL; Funck-Brentano C; Jaillon P
Clin Pharmacol Ther; 2002 Jun; 71(6):468-78. PubMed ID: 12087350
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
12. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
13. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Robl JA; Sun CQ; Stevenson J; Ryono DE; Simpkins LM; Cimarusti MP; Dejneka T; Slusarchyk WA; Chao S; Stratton L; Misra RN; Bednarz MS; Asaad MM; Cheung HS; Abboa-Offei BE; Smith PL; Mathers PD; Fox M; Schaeffer TR; Seymour AA; Trippodo NC
J Med Chem; 1997 May; 40(11):1570-7. PubMed ID: 9171867
[TBL] [Abstract][Full Text] [Related]
14. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
[TBL] [Abstract][Full Text] [Related]
15. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
Vesterqvist O; Reeves RA
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
[TBL] [Abstract][Full Text] [Related]
16. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
[TBL] [Abstract][Full Text] [Related]
17. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
Korshunov VA; Massett MP; Carey RM; Berk BC
J Vasc Res; 2004; 41(2):148-56. PubMed ID: 15004434
[TBL] [Abstract][Full Text] [Related]
18. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
[TBL] [Abstract][Full Text] [Related]
19. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
20. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
